163 results about "Cefixime" patented technology

The invention discloses a cephalosporin suspension granule of which the formula composition comprises drug active ingredients, excipient, suspending agent, disintegrating agent, flavoring agent, coloring agent, stabilizing agent, adhesive and spice. The granule takes cefixime, cefprozil, cefaclor or cefdinir as the main drug ingredient, disintegrating agent and suspending agent with a certain quantity are added into the formula to ensure that the effective ingredients are dissolved out, and the solution has favorable suspending effect. Meanwhile, the invention also discloses a preparation method of the cephalosporin suspension granule, which adopts the wet granulation method to prepare granules and adopts the fluidized bed drying method to dry. The invention adopts the fluidized bed drying technology, so that compared with the traditional oven drying, the invention has the advantages of short drying time, small influence on active matter quality and the like, not only ensures product quality but also improves production efficiency. The granule prepared by the formula of the invention has solid granularity and lowers damage to the granule by fluidized drying.

The invention provides a method for preparing cefixime, which belongs to the medicine synthesis technical field and comprises the steps of preparation of 7-AVCA, preparation of cefixime methyl ester, preparation of the cefixime and so on. The method aims at the prior amino de-protection to make an improvement, and uses penicillin acylase to substitute trifluoroacetic acid and so on in the prior process to ensure that an amino de-protection reaction is greatly improved, the use of organic solvents can be completely avoided, and acylase can also be reused at the same time. Methylene dichloride and tetrahydrofuran solvents in the prior process are substituted by adopting alcohol, ketone or ester solvents, so that an amidation reaction is greatly improved, which ensures that reaction solvents are easy to recover and reuse, can reduce production cost, reduce the discharge of waste liquid, reduce the pollution to the environment, can completely recover a byproduct, namely mercaptobenzothiazole produced by the reaction, improve the atom utilization rate of reaction raw-materials, and greatly improve the hydrolyzation and crystallization of subsequent products and the quality of a finished product.

A pharmaceutical composition comprising a solid unit dosage form comprising: one or more of pharmaceutically active ingredients selected from valacyclovir, olanzapine, voriconazole, topotecan, artesunate, amodiaquine, guggulosterone, ramipril, telmisartan, tibolone, atorvastatin, simvastatin, amlodipine, ezetimibe, fenofibrate, tacrolimus, valgancyclovir, valsartan, clopidrogel, estradiol, trenbolone, efavirenz, metformin, pseudoephedrine, verapamil, felodipine, valproic acid/sodium valproate, mesalamine, hydrochlorothiazide, levosulpiride, nelfinavir, cefixime and cefpodoxime proxetil in combination with a water insoluble polymer and/or a water soluble polymer. Methods for making the pharmaceutical composition are also disclosed.

The invention belongs to the technical field of pharmaceutical preparation, and in particular relates to a cefixime dispersible tablet and a method for preparing the same. The method comprises the following steps: firstly, weighing cefixime, starch, microcrystalline cellulose, partially cross-linked polyvinylpyrrolidone, partially cross-linked sodium carboxymethyl cellulose, and partially low substituted-hydroxypropyl cellulose, and mixing the components evenly; secondly, dripping 5 percent polyvinylpyrrolidone K30 ethanol solution into the mixture prepare a soft material, and performing granulating through a sieve of between 18 and 24 meshes; thirdly, drying wet particles at a temperature of between 50 and 80 DEG C, palletizing the particles through the sieve of between 18 and 24 meshes, adding the remaining cross-linked polyvinylpyrrolidone, the remaining cross-linked sodium carboxymethyl cellulose, and the remaining low substituted-hydroxypropyl cellulose, magnesium stearate and superfine silica gel powder into the mixture to be mixed evenly, and tabletting the mixture to obtain the required cefixime dispersible tablet. The cefixime dispersible tablet has the characteristics of rapid disintegration with water, even dispersion, high dissolution, and convenient taking and carrying around.

A novel 4-halo-2-oxyimino-3-oxo butyric acid-N,N-dimethyl formiminium chloride chlorosulfate of formula (I) useful in the preparation of cephalosporin antibiotics

wherein

X is chlorine or bromine; R is hydrogen, C_1-4 alkyl group, an easily removable hydroxyl protective group, —CH₂COOR₅, or —C(CH₃)₂COOR₅, wherein R₅ is hydrogen or an easily hydrolysable ester group. The compound of formula (I) is prepared by reacting 4-halo-2-oxyimino-3-oxobutyric acid of formula (IV¹),

wherein X, R and R₅ are as defined above, with N,N-dimethylformiminium chloride chlorosulphate of formula (VII)

in an organic solvent at a temperature ranging from −30° C. to −15° C. The cephalosporins that may be prepared from the intermediate include cefdinir, cefditoren pivoxil, cefepime, cefetamet pivoxil, cefixime, cefmenoxime, cefodizime, cefoselis, cefotaxime, cefpirome, cefpodoxime proxetil, cefquinome, ceftazidime, cefteram pivoxil, ceftiofur, ceftizoxime, ceftriaxone and cefuzonam.

The invention provides a method for preparing novel cefixime tablets and cefixime capsules. In the method, cefixime, a solubilizer and water soluble auxiliary materials are micronized and then mixed with other auxiliary materials, and the obtained products are granulated by a dry method, so that the stability of cefixime tablets and cefixime capsules is improved, and the dissolution rate of cefixime is also raised. The cefixime can be quickly absorbed by a patient after the patient takes the cefixime tablets and cefixime capsules, the plasma peak time is shortened and the plasma concentration can be quickly stabilized at a higher level, so that the treating effect is improved.

The invention relates to a cefixime compound and the preparation method thereof. In the preparation method of the cefixime compound, a cefixime crude product prepared by the prior art is processed to gain comparatively purer cefixime compound by the following procedures: aqueous alkali is added to raw materials of the cefixime crude product, or the cefixime crude product is dissolved in organic solvent and reacts with the added aqueous alkali, the pH value is adjusted, and the reaction continues until clarification to obtain cefixime saline solution; and the cefixime elaboration product can be obtained after the sequential operations of adding active carbon for adsorption and filtration, adding acid solution into filter liquor, adjusting the pH value, separating out crystals, filtrating, rinsing and drying.

The invention discloses an orally disintegrating cefixime tablet and its preparation, wherein the ingredients include (by weight ratio): cefixime 10.0-35.0%, crystalline cellulose 0-10%, lactose starch 0-35%, mannitol 35.0-59%, cross-linked sodium carboxymethylcellulose 4.0-15.0%, Kollidon 1.0-5.0%, sodium dodecylsulfate 0.01-1.0%, and silica gel powder 0.01-0.5%, the preparing process comprises the following steps, mixing the medicinal materials homogeneously, charging water, ethanol or their mixture, granulating and drying, mixing homogeneously with miropowdered silica gel and tabletting.

The invention discloses a chromogenic medium used for detecting esherichia coli O157:H7. The medium comprises agar, peptone, beef extract powder, sodium chloride, sorbitol, inositol, neutral red, beta-galactosidase chromogenic substrate, beta-glucuronidase chromogenic substrate, isopropyl-beta-D- thiogalactopyranoside, natrium taurocholicum, potassium tellurite and cefixime. The chromogenic medium used for detecting esherichia coli O157:H7 of the present invention has the advantages of high sensitivity, good specificity, direct bacterial strain discrimination according to colony color, short detection period and strong operationality, is suitable for treating high-reflux samples, is capable of comprehensively, systematically and accurately detecting and preliminarily identifying the esherichia coli O157:H7 in food production and environment, and provides a novel approach for rapidly detecting the microbes.

The invention discloses a method for preparing cefixime dispersible tablets, relates to the field of pharmaceutical preparation and particularly relates to cefixime dispersible tablets which are anti-infective agents and the method for preparing the cefixime dispersible tablets. Cefixime serves as an active pharmaceutical ingredient of the cefixime dispersible tablets and auxiliary materials are added in the cefixime dispersible tablets. The auxiliary materials include solubilizing agents, filling agents, lubricating agents, bonding agents and disintegrating agents. The cefixime dispersible tablets include, by weight, 15%-60% of the micronized cefixime, 10%-70% of the filling agents or diluents, 1%-20% of the disintegrating agents, 0.3%-5% of the lubricating agents, 0.5%-10% of the bonding agents and 0.5%-5% of the solubilizing agents, wherein grain diameters of the micronized cefixime range from 20 mu m to 120 mu m. The method has the advantages that the dissolving speed of the cefixime dispersible tablets is rapid and the dissolving is complete.

A process for preparingcefixime from perhalate includes reaction between compound A, perhalognic acid and organic protonic acid to obtain cefixime perhalate, removing protective radical, and setting free.

The invention relates to a cefixime submicro-emulsion solid preparation and a novel application thereof, in particular to a solid preparation of cefixime processed by micro-emulsification and a novel application thereof. The cefixime submicro-emulsion solid preparation comprises cefixime, an emulsifying agent and an emulsifying aid agent, wherein the active component of the cefixime is processed by applying a micro-emulsification technology. The stability is enhanced, the solubility is increased, and the problem of low leaching degree is solved.

The invention discloses a Ceftazidime pharmaceutical compound with a molecular formula of C16H13N5Na2O7S2, whose molecular weight is 497.5, the pharmaceutical compound is prepared by reacting 1 mol of Ceftzaidime with 2mol of sodium bicarbonate under normal temperature and ordinary pressure, charging ethanol for crystallization, recrystallization, and vacuum drying at below 60 deg. C.

The present invention provides an improved process for the preparation of cefixime of formula (I), with an improved quality having/possessing better color and solubility.

The invention discloses a cefixime oral administration mixed suspension and a preparation method thereof, in order to meet the requirement of special medicament taking crowds on the taking of cefixime. The cefixime oral administration mixed suspension per 100ml comprises the following components: 0.5-4.0g of cefixime, larger than 0-20.0g of thickening suspension assistant agent, a cosolvent, a flavoring agent, a preservative and the balance of non-aqueous liquid medium. The preparation method comprises the following steps of: dissolving the preservative into the cosolvent; adding the thickening suspension assistant agent into the non-aqueous liquid medium, stirring and dissolving; adding solutions of the flavoring agent, the preservative and the cosolvent uniformly stirring; and adding cefixime micropowder and uniformly stirring and spreading. Compared with the prior art, the unstable cefixime in water is made into the oral administration mixed suspension by using non-aqueous liquid as a dispersing medium, and the invention solves the problem of stability, has good taste and simple preparation method, is convenient for children, old people and a dysphagia patient to accept and is suitable for industrialized production.

The invention relates to a slow-release tablet prepared from cefixime and pharmaceutically acceptable auxiliary materials. The slow-release tablet is characterized in that: the slow-release tablet consists of the following raw materials and auxiliary materials in portion by weight: 200 portions of cefixime(counted as an anhydride), 20 to 200 portions of at least one pharmaceutically acceptable slow-release material which can control the drug to continuously and completely release, 20 and 400 portions of a pharmaceutically acceptable excipient and 5 to 100 portions of at least one solubilizer which can effectively improve the release rate of the drug. The slow-release tablet is easy to prepare and facilitates the industrialized production.

The invention discloses a cefixime pharmaceutical composition for injection, which is prepared from active component cefixime and solubility promoter by the weight proportion of 1-15 : 1 thus fully mixing in asepsis environment, the solubility promoter is selected from alkaline amino acids, alkali metals, or the inorganic or organic acid salt of alkaline-earth metals.

The invention relates to a cefixime dry suspension and a preparation method thereof, belonging to the technical field of pharmaceutical preparations. The cefixime dry suspension contains 40-60 parts by weight of cefixime crystal form, wherein the X-ray powder diffraction pattern of the cefixime crystal form has characteristic absorption peaks at reflection angles 2theta of 11.14 degrees, 11.50 degrees, 14.14 degrees, 16.60 degrees, 16.90 degrees, 17.18 degrees, 20.50 degrees, 21.40 degrees, 22.20 degrees, 22.80 degrees, 22.94 degrees and 28.54 degrees. As the cefixime crystal form is used by the cefixime dry suspension, absorption of the cefixime dry suspension in human bodies is accelerated and the bioavailability is improved, thus the curative effects are improved. The cefixime dry suspension has better stability and dissolution effect and improves the use efficiency of unit dose.

The invention relates to a cefixime crystal, a preparation method thereof and a tablet composition containing the crystal. The cefixime crystal can significantly improve the stability and dissolvability. The tablet core of the cefixime tablet composition is prepared by the following components: 35-65 parts of cefixime crystals, 17-29 parts of starch, 3-6 parts of hydroxypropyl cellulose, 3-5 parts of carboxymethyl starch sodium, 7-13.5 parts of microcrystalline cellulose, 0.3-0.7 parts of starch sodium, and 0.3-0.7 parts of magnesium stearate. The cefixime tablet combination prepared by the invention has good stability, and stable effective component contents, and is an ideal cefixime preparation.

A medicine in the form of tablet, capsule, particle, oral liquid, or suspension for treating pulmonary infectious diseases is prepared from ambroxol hydrochloride and one of cefixime, cefetamet sodium and cefetamet hydrochloride.